1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Baclofen |
| brand | String | Lioresal (oral, intrathecal pump), Ozobax / Fleqsuvy (oral suspension), Gablofen (intrathecal), Lyvispah (oral granules) |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Skeletal muscle relaxants|Skeletal muscle relaxant (centrally-acting)]] • [[:Category:Antispastics|Antispastic]] • [[:Category:GABA-B receptor agonists|GABA-B receptor agonist]] |
| mechanism | String | |
| uses | String | '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"' |
| starting_dose | String | Oral: 5 mg PO TID, titrate by 5 mg per dose every 3 days. Intrathecal: bolus test dose, then continuous infusion via implanted pump |
| preparations | String | Tablets 5, 10, 20 mg; oral suspension 5 mg/5 mL (Ozobax, Fleqsuvy); intrathecal injection 50, 500, 1000, 2000 mcg/mL (Lioresal Intrathecal, Gablofen); oral granules (Lyvispah) |
| fda_max | String | 80 mg/day oral (higher off-label) |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral • intrathecal (via implanted infusion pump) |
| onset | String | 1-2 hours (oral) |
| duration | String | 4-6 hours (oral, TID-QID dosing) |
| halflife | String | 3-4 hours'"`UNIQ--ref-00000026-QINU`"' |
| bioavailability | String | ~70-85% (oral)'"`UNIQ--ref-00000027-QINU`"' |
| pregnancy | String | Limited human data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> |
| legal | String | [[USLegal:Prescription only|Rx-only]] in US. Not a controlled substance'"`UNIQ--ref-00000028-QINU`"' |
